Monitor for any follow-up filings or news that might explain the timing of these sales, but this level of selling by multiple executives is common at large-cap biotech firms and not inherently negative. No material fundamental change is indicated.
VRTX drugs
VRTX drug pipeline →- ▲ povetacicept 6/10 Filed/PDUFA (BLA under FDA review for accelerated approval in IgAN); Phase 3 (RAINIER in IgAN); Phase 2b/3 (OLYMPUS in p · PDUFA date Nov 30, 2026
- ● inaxaplin 5/10 Phase 2/3
- ▲ ALYFTREK 4/10 Approved
- ● JOURNAVX 4/10 Approved
- ● TRIKAFTA 4/10 Approved
- 6 more · All VRTX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 25 $482.92entry
- T+1 · 9mo ago −0.58%α −0.03% · $480.12
- T+5 · 9mo ago −1.32%α −0.22% · $476.54
- T+20 · 8mo ago −5.79%α −0.55% · $454.96
- T+60 · 6mo ago −10.87%α −17.82% · $430.44
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Seven executives at Vertex Pharmaceuticals sold shares in a coordinated cluster over a 3-day window, with total open-market sales amounting to $4.4 million. All transactions were direct sales at market prices, including a $1.2 million sale by the Chief Commercial Officer. The activity represents less than 0.01% of the company's $123.5B market cap and aligns with routine insider selling patterns.
Key Financial Metrics
Key Facts
- 8 open-market share sales by 8 different insiders over 7 days
- Total value of sales: $4,453,244.64
- All sellers are C-suite executives, including EVPs across commercial, legal, scientific, technical, and medical functions
- No purchases, grants, or derivative exercises in the cluster
- Largest sale: Duncan McKechnie (Chief Commercial Officer), $1.216M
- Sales occurred at prices between $480.31 and $486.35 per share
- Total insider sales in the past 30 days now amount to $4.6M
Financial Impact
$4.45 million in open-market sales over 7 days
Risk Factors
- Perception risk if selling continues or accelerates ahead of earnings or regulatory decisions
- Potential misinterpretation by retail investors as a negative signal despite routine nature
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (8 trades, 7d window) | cluster-VRTX-1772573390984 |
Track record
21 reports on VRTX
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +10.87% at T+60 after the Feb 25, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $537.79 Now $531.45 −1.18% settles Nov 24
- Nov 16, 20261d ago 144 Neutral 2/10 Entry $543.10 Now $531.45 −2.15% settles Nov 23
- Nov 16, 20261d ago 144 Neutral 1/10 Entry $544.98 Now $531.45 −2.48% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $542.00 Now $531.45 −1.95% settles Nov 23
- Nov 12, 20265d ago 144 Neutral 2/10 Entry $542.62 Now $531.45 −2.06% settles Nov 19
- Nov 6, 202611d ago 144 Neutral 2/10 Entry $547.09 to $538.60 Now $531.45 −2.86% ▼ −1.55% −4.15% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $530.76 to $547.89 Now $531.45 +0.13% ▲ +3.23% +3.81% vs SPY
- Oct 22, 202626d ago 3 Neutral 2/10 Entry $523.93 to $558.88 Now $531.45 +1.44% ▲ +6.67% +7.23% vs SPY
- Oct 20, 202628d ago 8-K Neutral 2/10 Entry $524.52 to $521.03 Now $531.45 +1.32% ▼ −0.67% −0.22% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $500.36 to $517.49 Now $531.45 +6.21% ▲ +3.42% +3.57% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers